Orphan Drug Status

January 27, 2020

Rare diseases top another strong year for novel drug approvals

A clutch of swift FDA decisions boosted average US drug approval times in 2019, helping biopharma to deliver another bumper crop of new medicines.

October 03, 2019

Nippon Shinyaku tries to go where Sarepta faltered

February 16, 2018

Snippet roundup: Alzheimer’s doubts grow and Bavencio's Javelin falls short

January 16, 2018

Blockbuster approvals line up for biopharma in 2018

2018 shaping up to be a bumper approval year, as Juno Therapeutics, Epizyme and Avexis line up to launch potential blockbusters.

July 13, 2017

Leukaemia options begin to improve for elderly patients

January 18, 2017

Faster FDA adds a positive spin to 2016's disappointing approval record

October 11, 2016

Therapy focus – Spinal muscular atrophy pipeline awaits nusinersen news

September 22, 2016

Priority review vouchers revisited

September 08, 2016

Just like buses, three come at once in leukaemia regulatory queue

September 06, 2016

Interview – Array plays the cardiovascular card

August 27, 2015

Three years on, another Duchenne showdown beckons

Load More